Tone mix
Week by week 47 weeks
Share of Beam Therapeutics Inc. Common Stock's 132 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Jun 22, 2026 · tone +100Resonac signs BEAM deal for low Earth orbit chip production+80
- Week of Dec 22, 2025 · tone +100BEACON Trial Data Makes Beam Therapeutics (BEAM) an Attractive Buy+69
- Week of Oct 13, 2025 · tone +85Jim Cramer on Beam Therapeutics: "That's the Speculative Bottom There"+60
- Week of Jan 26, 2026 · tone +100Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM)+60
- Week of Aug 25, 2025 · tone 0Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences-59
- Week of Jan 5, 2026 · tone +95Beam Therapeutics (NASDAQ:BEAM) Stock Rating Upgraded by UBS Group+57
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Beam Therapeutics Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 2 | 0 |
| Last 30 sessions | 12 | +9 |
| Last 90 sessions | 36 | +14 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Monday, October 26, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletHead-To-Head Contrast: Beam Therapeutics (NASDAQ:BEAM) & Novavax (NASDAQ:NVAX)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Head-To-Head Contrast: Beam Therapeutics (NASDAQ:BEAM) & Novavax (NASDAQ:NVAX) | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 22, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 2 outletsRecent Analysts' Ratings Changes for Beam Therapeutics (BEAM)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Recent Analysts' Ratings Changes for Beam Therapeutics (BEAM) | www.dailypolitical.com | 2 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 19, 2026
2 headlines, average tone +45: 1 positive, 1 neutral and 0 negative. Showing all 2.
- www.fool.com · 2 outletsCathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?Positive
- www.themarketsdaily.com · 2 outletsBeam Therapeutics (NASDAQ: BEAM) CEO sells 50,000 shares after option exerciseNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? | www.fool.com | 2 | Positive |
| Beam Therapeutics (NASDAQ: BEAM) CEO sells 50,000 shares after option exercise | www.themarketsdaily.com | 2 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 15, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 2 outletsResearch Analysts' Updated EPS Estimates for October 14th (ACI, ALB, AMAT, AVR, BBY, BEAM, BMEA, BP, BRKR, BWY)Neutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Research Analysts' Updated EPS Estimates for October 14th (ACI, ALB, AMAT, AVR, BBY, BEAM, BMEA, BP, BRKR, BWY) | www.dailypolitical.com | 2 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 13, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.manilatimes.net · 1 outletBeam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual CongressNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual Congress | www.manilatimes.net | 1 | Neutral |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Beam Therapeutics Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.